A SUBJECT-BLIND, INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING SUBCUTANEOUS DOSES OF UCB4019 IN HEALTHY SUBJECTS

Trial Profile

A SUBJECT-BLIND, INVESTIGATOR-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING SUBCUTANEOUS DOSES OF UCB4019 IN HEALTHY SUBJECTS

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs UCB 4019 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; First in man
  • Sponsors UCB
  • Most Recent Events

    • 08 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 14 Dec 2016 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.
    • 14 Dec 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top